Praxis Precision Medicines
Edit info- Founded: 2015
- Location: Boston, MA
- Employee range: 50 - 200
- Clinical stage: Clin2
- Therapy area: Parkinson's
- Drug types: NEU, PED
- Lead product: Ulixacaltamide
- Funding: $59M stock Jun 2023; $219M IPO Oct 2020; $110M C1 Jul 2020; $100M total May 2020
- Investors: Blackstone Life Sciences, Novo Holdings, Vida Ventures, Eventide
praxismedicines.com linkedin.com job board
Business:
Genetic Neuroscience Treatments
Drug notes:
Also Clin2 essential tremor; PRAX-562 Clin2 epilepsy; PRAX-628 Clin1 focal epilepsy; PRAX-222 Clin1 epilepsy; 6 programs Clin0 CNS disorders
About:
Praxis Precision Medicines is developing therapies for central nervous system (CNS) disorders by using insights from genetics. CNS disorders are characterized by neuronal excitation-inhibition imbalance. Praxis is using four key principles to increase the probability of success of finding therapies: [1] genetics to focus on targets identified through human genetics, [2] translational tools, to validate targets, [3] patient-guided development strategies and [4] efficient and rigorous clinical development paths. Praxis currently has two lead clinical programs for Epilepsy - CerebrumTM, a small molecule platform and SolidusTM, an antisense oligonucleotide platform.
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com